Αποτελέσματα Αναζήτησης
ORTHO EVRA ® is a combination transdermal contraceptive patch with a contact surface area of 20 cm. 2. It contains 6.00 mg norelgestromin (NGMN) and 0.75 mg ethinyl estradiol (EE)....
Generic Allegra-D Approved. A combination of fexofenadine HCl and pseudoephedrine HCl in an extended-re-lease tablet (60 mg/120 mg) is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and chil-dren 12 years and older.
ORTHO EVRA is an estrogen/progestin combination hormonal contraceptive (CHC), indicated for the prevention of pregnancy in women who elect to use a transdermal patch.
FORMS, COMPOSITION AND PACKAGING section. INDICATIONS AND CLINICAL USE The EVRA® (norelgestromin and ethinyl estradiol) transdermal system is indicated for the prevention of pregnancy. The pharmacokinetic profile for the EVRA® transdermal system is different from that of an oral contraceptive.
EVRA® 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch PRESCRIBING INFORMATION . ACTIVE INGREDIENT(S): Norelgestromin (NGMN) and ethinyl estradiol (EE). Please refer to Summary of Product Characteristics (SmPC) before prescribing. INDICATION(S): Female contraception, intended for women of fertile age. Safety/efficacy
SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT. EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each 20 cm2 transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE).
The EVRA (norelgestromin and ethinyl estradiol) transdermal system, with a contact surface area of 20 cm2, is a thin, matrix-type transdermal system consisting of three layers. Each transdermal system contains 6.0 mg norelgestromin and 0.60 mg ethinyl estradiol (EE).
